Kwanan nan, Novo Nordisk ta fitar da rahoton rahoton kudi na 2022 bisa hukuma. Bayanai sun nuna cewa jimlar tallace-tallacen Novo Nordisk a cikin 2022 zai kai 176.954 biliyan Danish krone (US $ 24.994 biliyan, canjin canjin da aka sanar a cikin rahoton shekara-shekara, iri ɗaya a ƙasa), sama da 26% a shekara, ribar aiki za ta kai 74.809 biliyan Danish krone. (US $10.566 biliyan), sama da 28% a shekara, kuma net riba zai zama 55.525 Danish krone (US $ 7.843 biliyan), sama 16% a kowace shekara. Ayyukan yana da ban sha'awa sosai.

Daga ina ƙwararren Novo Nordisk ya fito? Amsar ita ce GLP-1 analog. A cikin bututun samfurin Novo Nordisk, ana iya raba samfuran zuwa nau'ikan nau'ikan nau'ikan nau'ikan nau'ikan nau'ikan nau'ikan nau'ikan nau'ikan nau'ikan nau'ikan nau'ikan nau'ikan nau'ikan nau'in nau'in nau'in nau'in nau'in nau'in nau'in nau'in nau'in nau'in nau'in nau'in nau'in nau'in nau'in nau'in nau'in nau'in nau'in nau'in nau'in nau'in nau'in nau'in nau'in nau'in nau'in nau'in nau'in nau'in nau'in nau'in nau'in nau'in nau'in nau'in) za a iya raba: GLP-1 analogues, insulin da analogues, abubuwan coagulation da sauran hormones na rayuwa, tare da siyar da krone biliyan 83.371 (dala biliyan 11.176, ban da alluran asarar nauyi), biliyan 52.952 Danish. krone (dala biliyan 7.479), da biliyan 11.706 na Danish (dala biliyan 1.653) da kuma krone biliyan 7.138 (dala biliyan 1.008), bi da bi. Daga cikin analogues na GLP-1, tallace-tallace na Liraglutide hypoglycemic allura yana raguwa kowace shekara, yayin daSemaglutideyana da ɗaukar ido sosai, tare da jimlar tallace-tallace na dala biliyan 10.882 a cikin 2022.